#### 1 Association of CD7<sup>+</sup>CXCR3<sup>+</sup> CAR T cells with long-term remission in R/R DLBCL

- 2 Robin Bartolini<sup>1\*</sup>, Lionel Trueb<sup>2\*</sup>, Douglas Daoudlarian<sup>1\*</sup>, Victor Joo<sup>1</sup>, Alessandra Noto<sup>1</sup>,
- 3 Raphaël Stadelmann<sup>3</sup>, Bernhard Gentner<sup>2,4,5,6</sup>, Craig Fenwick<sup>1</sup>, Matthieu Perreau<sup>1</sup>, Georges
- 4 Coukos<sup>2,4,5,6</sup>, Giuseppe Pantaleo<sup>1</sup>, Caroline Arber<sup>2,3,4,5,6</sup>, Michel Obeid<sup>1#</sup>
- <sup>5</sup> <sup>1</sup>Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of
- 6 Medicine, Immunology and Allergy Service, Rue du Bugnon 46, CH-1011 Lausanne,
- 7 Switzerland
- 8 <sup>2</sup>Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of
- 9 Oncology, Immuno-Oncology Service, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland
- 10 <sup>3</sup>Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Departments of

11 Oncology and Laboratory Medicine, Hematology Service, Rue du Bugnon 46, CH-1011

- 12 Lausanne, Switzerland
- 13 <sup>4</sup>Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland.
- <sup>5</sup>Swiss Cancer Center Léman, Lausanne, Switzerland.
- 15 <sup>6</sup>AGORA Cancer Research Center, Lausanne, Switzerland.
- 16 \*contributed equally to this work
- 17

#### 18 *≠***Corresponding author:**

- 19 Pr. Michel Obeid, MD-PhD
- 20 Lausanne Center for Immuno-Oncology Toxicities LCIT
- 21 Immunology and Allergy Division, Rue du Bugnon 17, 1011 Lausanne, Switzerland
- 22 Centre Hospitalier Universitaire Vaudois (CHUV)
- 23 Email: michel.obeid@chuv.ch
- 24
- 25 Key words: Anti-CD19 CAR T cell infusion products, immune cell phenotypes, predictive
- 26 biomarkers, CXCR3, CD7, NKG2D, LAG-3, CD71.
- 27
- 28
- 29
- 30 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 31 Abstract

32 **Background.** CAR T-cell therapy is the standard of care for R/R DLBCL, but more than half 33 of patients fail to achieve long-term remission. Identification of cellular biomarkers in CAR T-34 cell infusion products (IPs) that predict complete remission beyond six months may guide the 35 development of strategies to improve outcomes. 36 **Methods.** IPs from 13 R/R DLBCL patients were analyzed using a 39-marker mass cytometry 37 panel, comparing cell populations between long-term responders (R) and non-responders (NR). 38 Both unsupervised and supervised analyses were performed. Longitudinal blood samples were 39 analyzed for 30 days to track CAR T-cell subpopulation dynamics. 40 **Results.** At a median follow-up of 13.5 months, median progression-free survival (PFS) was 41 13.3 months (95% CI: 9.7-24.3) in R (n=8) versus 3.5 months (95% CI: 0.5-5.4) in NR (n=5). 42 The HR for PFS was 56.67 (95% CI: 7.3-439.3; P=0.0001). A subset of CD3<sup>+</sup>CXCR3<sup>+</sup>CD7<sup>+</sup> 43 CAR T-cells found in both CD4<sup>+</sup> and CD8<sup>+</sup> populations was significantly enriched in R and 44 expressed higher levels of perforin, granzyme B, and NKG2D (restricted to CD8<sup>+</sup>). NR had 45 more CXCR3<sup>+</sup>CD7<sup>+</sup>LAG3<sup>+</sup> CAR T-cells. CD3, CD7, CXCR3, and NKG2D cell surface levels 46 were higher in R, whereas LAG3, Ki67, and CD71 were elevated in NR. A predictive cut-off of 47 ratio CD3<sup>+</sup>CXCR3<sup>+</sup>CD7<sup>+</sup>LAG3<sup>+</sup>CAR<sup>+</sup> **T-cells** < 0.83 and 48 CD3<sup>+</sup>CXCR3<sup>+</sup>CD7<sup>+</sup>NKG2D<sup>+</sup>CAR<sup>+</sup> T-cells >1.034 yielded a predictive accuracy of 0.92. 49 Serum CXCL9 and CXCL10 levels were not different between groups.

50 **Conclusions.** Increased frequency of CAR T-cells expressing CD7, CXCR3 and NKG2D in R

51 versus LAG3 and CD71 in NR emerged as strong correlates of therapeutic outcome.

52

53

#### 54 Introduction

55 Despite notable clinical successes, about half of all patients with relapsed and/or refractory 56 diffuse large B-cell lymphoma (R/R DLBCL) do not achieve long-term remissions with currently available CAR T-cell therapy<sup>1</sup>. Predictive factors determining the efficacy remain 57 58 incompletely understood. The phenotypic composition of infusion products (IPs) is important, 59 as defined T-cell subsets have been associated with enhanced antitumor activity in vivo<sup>2</sup>. 60 Patients treated with axicabtagene ciloleucel (axi-cel), achieved higher complete response (CR) rates when their IPs were enriched for CD8 memory T-cell phenotypes<sup>3</sup>. These memory-like T 61 62 cells are believed to confer sustained proliferative capacity and persistence leading to better 63 clinical outcomes.

64 Moreover, the expression of inhibitory receptors on CAR-T cells has been linked to therapeutic 65 failure. Human CAR-T cells with intrinsic PD-1 blockade overcome tumor-driven inhibition<sup>4</sup>. Additionally, PD-1 inhibition enhanced the function of CAR-T cells in patient with R/R 66 DLBCL<sup>5</sup>. Notably, exhaustion markers like LAG-3 and TIM-3 on intratumoral CD8<sup>+</sup> T cells 67 68 by day 7 post-infusion correlate with poorer outcomes in patients receiving axi-cel<sup>3</sup>. This 69 suggests that regulatory and exhausted T-cell phenotypes may limit the efficacy of CAR T-cell 70 therapy. Similar patterns have been reported in chronic lymphocytic leukemia (CLL), where 71 patients achieving durable remissions following CAR T-cell therapy received infusion products 72 with lower frequencies of CD8<sup>+</sup> T cells co-expressing inhibitory receptors like PD-1, LAG-3, 73 and TIM-3<sup>6</sup>. Conversely, higher co-expression of these inhibitory receptors correlated with 74 suboptimal responses, highlighting the importance of T-cell fitness and the intricate balance between activation and inhibition in driving successful outcomes<sup>6,7</sup>. 75

These findings highlight the critical need for a deeper understanding of the phenotypic
 characteristics that predict CAR T-cell efficacy. By identifying specific CAR T-cell phenotypes

associated with successful treatment outcomes, existing IPs and clinical treatment algorithms
can potentially be optimized to enhance patient outcomes. Moreover, data from correlative bedto-bench studies can be exploited for the development of next generation potency-enhanced
CAR T-cell products.

82

To address this knowledge gap, we performed a comprehensive analysis conducted an extensive analysis of the cellular and phenotypic diversity within CAR T-cell infusion products using a 39-marker mass cytometry panel. The objective of this study was to identify predictive markers of durable responses and to improve our comprehension of the factors influencing the longterm efficacy of CAR T-cell therapy in patients with R/R DLBCL.

88

#### 89 **METHODS**

90 Patient Consent, Ethical Approval, and Sample Collection. Participants provided informed 91 consent for the research use of their cells, blood samples, and data through a "consentement 92 général" process, ensuring data confidentiality. Enrollment followed Article 34 of the Swiss 93 Federal Law on Human Research, and the study received approval from the Cantonal Ethics 94 Committee (CER-VD). Biological samples were collected during routine clinical care, with 95 residual CAR T-cells obtained by washing the CAR T-cell infusion bag & line after infusion. 96 Peripheral blood mononuclear cells (PBMCs) were collected from treated patients at multiple 97 time points from week 1 to week 4 post-infusion.

98 Mass Cytometry Analysis. A mass cytometry panel comprising 39 markers was developed 99 and validated for this study with the corresponding fluorescently labeled antibody clones from 100 BD Biosciences (Supplementary Table 1). The analysis was compared to healthy volunteer 101 data to establish baselines. This panel enabled high-dimensional analysis of cellular

phenotypes, offering insights into IP composition and immune cell dynamics in CAR T-celltherapy recipients.

104 Study Design and Population. This observational study was conducted at the CHUV's 105 Immuno-Oncology and Immunology and allergy Service from January 2020 to May 2024. The 106 final analysis included 13 patients with relapsed/refractory (R/R) DLBCL receiving standard of 107 care CAR T-cell therapy and follow up (Supplementary Figure 1). 108 Oncologic Response Assessment. CAR T-cell therapy efficacy was assessed using PET/CT 109 scans at baseline, and 1-, 3- and 6-months post-infusion. 110 Response Definitions. Responders were those with no relapse on PET/CT for at least six 111 months post-infusion. Non-responders either did not respond at the 30-day evaluation or 112 experienced disease progression before the six-month follow-up. 113 Statistical Analysis. Statistical analyses were performed using GraphPad Prism 10.1.2 and

MATLAB R2023b. ROC curve analysis and clustering were conducted, with optimal cutoffs determined using Youden's index. Cox proportional hazard model was performed using R and *"survival package*". Clustering was performed using k-means clustering MATLAB.

117

#### 118 **RESULTS**

#### 119 **Patient clinical characteristics.**

120 A total of 41 patients treated with CAR T-cell therapy at the University Hospital of Lausanne

121 (CHUV) were identified. CAR-T infusion data were analyzed for 13 patients with R/R DLBCL

122 (study flowchart **Supplementary Figure 1**). Patient characteristics are summarized in **Table** 1.

- 123 The median follow-up was 13.5 months at the data cut-off date (June 15, 2024). The median
- 124 patient age was 61 years (range 28-78), with 38% aged >65 years and 77% male (n=10/13).
- 125 The majority of patients (54%, n=7/13) had stage III or IV disease. Treatments included
- 126 axicabtagene ciloleucel (axi-cel) (85%, n=11/13) and tisagenlecleucel (tisa-cel) (15%, n=2/13).

127 Cytokine release syndrome (CRS) was observed in 85% of patients, with 69% exhibiting mild 128 (grades 1-2) and 15% demonstrating severe (grades 3 or higher) CRS, according to the ASTCT 129 Consensus grading system<sup>8</sup>. The most common late (after 30 days) hematologic toxicity 130 (ICAHT) was grade 3 or higher thrombocytopenia (38%) and neutropenia (31%), only grade 3 131 or higher have been reported in the Supplementary Table 2. Regarding CRS treatment, 85% 132 received only tocilizumab (TCZ), 38% received corticosteroids (CS) and 8% received 133 canakinumab (CAN). Four patients were treated in second line, all others in third or higher line, 134 and 31% (n=4/13) had relapsed after autologous stem cell transplantation (Supplementary 135 Table 2).

136

#### 137 Distinct CAR T-cell populations in infusion products associated with long-term remission

138 We used a 39-marker panel to identify CAR T-cell populations associated with long-term 139 remission. We first examined the frequencies of total CAR<sup>+</sup>CD4<sup>+</sup> and CAR<sup>+</sup>CD8<sup>+</sup> T-cells and 140 the CD4/CD8 ratio but found no significant association with outcomes (Supplementary Figure 141 2). We next extended our analysis to other markers and evaluated their frequencies and 142 expression levels within the total CAR<sup>+</sup>CD3<sup>+</sup> compartment and the CAR<sup>+</sup>CD3<sup>+</sup>CD4<sup>+</sup> and 143 CAR<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup> subsets. Among all analyzed markers, we observed significant differential 144 expression of LAG3, Ki67, CD71, CXCR3, CXCR5, CD3, and CD7 between responders (R) 145 and non-responders (NR) (Figure 1, Supplementary Figure 3). Specifically, IPs of NR 146 contained significantly higher proportions of LAG3<sup>+</sup>, Ki67<sup>+</sup>, and CD71<sup>+</sup> CAR T-cells in total 147 CD3<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> compartments, and mean metal intensity (MMI) of these 148 markers was also significantly increased. Conversely, CAR T-cells in IPs of R expressed higher 149 levels of CD3, CD7, CXCR3, and CXCR5 by MMI. Notably, NKG2D expression was higher 150 in R compared to NR but only within the CD8<sup>+</sup> compartment, consistent with NKG2D's 151 restriction to CD8<sup>+</sup> T-cells. Analysis of these markers alone (on the total CAR<sup>+</sup>CD3<sup>+</sup>

compartment) demonstrated significant performance in discriminating between R and NR using
receiver operating characteristic (ROC) curve analyses, with area under the curve (AUC) values
ranging from 0.85 to 0.975 and p-values from 0.0404 to 0.0054 (Supplementary Figure 4)

155

# 156 Identification of a responder-enriched CD3<sup>+</sup>CXCR3<sup>+</sup>CD7<sup>+</sup>CAR<sup>+</sup> T-cell population in 157 infusion products.

158 Next, we investigated whether these identified markers were co-expressed, defining a 159 population that could predict long-term remission. Initially, we used unsupervised UMAP 160 analysis, which divided the CAR<sup>+</sup>CD3<sup>+</sup> compartment into two clusters: CD4<sup>+</sup> cells (low 161 NKG2D expression) and CD8<sup>+</sup> cells. In the CD4<sup>+</sup> cluster, NR had higher frequencies of 162 populations C4-6 and C4-7, characterized by low CXCR3 and CD7 but high CD71; C4-7 also 163 had elevated Ki67 and LAG3 (Supplementary Figure 5). In the CD8<sup>+</sup> compartment, cluster 164 C8-3 was enriched in R, expressing high CXCR3 and CD7 but low Ki67 and LAG3. 165 Conversely, cluster C8-6, enriched in NR, showed lower CXCR3, CD7, and NKG2D but higher 166 LAG3 compared to C8-3 (Supplementary Figure 5). Given the critical importance of CXCR3 167 and CD7 in defining R and NR, we focused our supervised analysis on CAR<sup>+</sup>CXCR3<sup>+</sup>CD7<sup>+</sup> 168 double-positive cells. In R, CXCR3<sup>+</sup>CD7<sup>+</sup> (CD3<sup>+</sup>CAR<sup>+</sup>) cells averaged 85%, compared to 65% 169 in NR. In the CD8<sup>+</sup> compartment, CXCR3<sup>+</sup>CD7<sup>+</sup> cells represented 90% of CD8<sup>+</sup>CAR<sup>+</sup> cells in 170 R versus 75% in NR (Figure 2A).

171

#### 172 Phenotypic characterization of the CD3<sup>+</sup>CXCR3<sup>+</sup>CD7<sup>+</sup>CAR<sup>+</sup> T-cell population.

We further characterized the CXCR3<sup>+</sup>CD7<sup>+</sup> double-positive population by comparing coexpression of various other markers to that of CXCR3<sup>+</sup>CD7<sup>-</sup>, CXCR3<sup>-</sup>CD7<sup>+</sup>, and CXCR3<sup>-</sup>CD7<sup>-</sup> populations. The CXCR3<sup>-</sup>CD7<sup>-</sup> population expressed the lowest levels of all markers analyzed, except for CD71, which was highly expressed compared to other populations. The

177 CXCR3<sup>+</sup>CD7<sup>+</sup> cells expressed the highest levels of perforin, granzyme B, and NKG2D, 178 indicating the strongest effector potential (Supplementary Figure 6). After identifying this 179 double-positive population in both IPs and longitudinal samples (Supplementary Figure 7), 180 we investigated whether other markers on CXCR3<sup>+</sup>CD7<sup>+</sup> cells were differentially expressed 181 between R and NR. Among all analyzed markers, we again observed significant differences in 182 the expression of CD3, CD7, Ki67, NKG2D, CD71, and LAG3 (Supplementary Figure 8). 183 We incorporated these markers one by one into the CXCR3<sup>+</sup>CD7<sup>+</sup> population. 184 CXCR3<sup>+</sup>CD7<sup>+</sup>LAG3<sup>+</sup> cells were twice as frequent in the IPs of NR (40% of CD3<sup>+</sup>CAR<sup>+</sup> cells) 185 compared to R (20%), a difference also observed in the CD4<sup>+</sup> and CD8<sup>+</sup> compartments (Figure 186 **2B**). Conversely, CXCR3<sup>+</sup>CD7<sup>+</sup>NKG2D<sup>+</sup> cells were significantly more frequent in the CD8<sup>+</sup> 187 compartment of R, reaching 80% of CD3+CD8+CAR+ T-cells compared to only 45% in NR 188 (Figure 2C). No significant differences were observed in the frequency of 189 CXCR3<sup>+</sup>CD7<sup>+</sup>CD71<sup>+</sup> cells between groups (Figure 2D). Interestingly, while the CXCR3<sup>+</sup>CD7<sup>+</sup> 190 population was also observed in the circulation of healthy individuals, these cells completely 191 lacked CD71 expression, exhibited very low LAG3 levels, and showed NKG2D levels 192 comparable to those observed in NR. NKG2D upregulation in CD3<sup>+</sup>CD8<sup>+</sup>CAR<sup>+</sup> T-cells seems 193 to be exclusive to R. This highlights profound phenotypic differences between normal memory 194 T-cells and CAR T-cells, suggesting that the CXCR3<sup>+</sup>CD7<sup>+</sup>CAR<sup>+</sup> population in responders is 195 uniquely endowed with cytotoxic capabilities essential for effective antitumor responses.

196

#### 197 The predictive value of marker ratios for six-month progression-free survival.

Given the established correlation between specific markers and patient survival, we sought to
determine whether the balance between positive and negative subpopulations for CD71, LAG3,
and NKG2D within the CXCR3<sup>+</sup>CD7<sup>+</sup> subset influences the prediction of treatment response.
We evaluated the ratios of CD71, LAG3, and NKG2D MMI within the CXCR3<sup>+</sup>CD7<sup>+</sup>

202 population across all CAR<sup>+</sup> T-cells as well as within CAR<sup>+</sup>CD4<sup>+</sup> and CAR<sup>+</sup>CD8<sup>+</sup> subsets, to 203 assess their predictive performance. The analysis demonstrated that all ratios-except for 204 NKG2D in CD3<sup>+</sup> cells and CD71<sup>+</sup> in CAR<sup>+</sup>CD8<sup>+</sup> cells—showed statistically significant 205 differences between R and NR. Optimal cutoff values were identified using the Youden index 206 and utilized to reclassify patient responses using forementioned ratios, all markers except 207 NKG2D in CD3 and CD71 in CAR<sup>+</sup>CD8<sup>+</sup> had ROC that were predictive, with accuracies 208 ranging from 0.77 to 0.92. Notably, LAG3 positivity and NKG2D negativity within the 209 CXCR3<sup>+</sup>CD7<sup>+</sup> population were linked to poorer PFS outcomes (Figure 3). We then examined 210 the expression levels of previously identified significant markers-CXCR3, CD7, NKG2D, LAG3, and Ki67-on various populations based on CD3+, CD4+, CD8+, and CXCR3+CD7+ 211 212 subsets to determine whether these levels could predict long-term remission. Our findings 213 revealed that all marker MMIs, except for Ki67 in the CD4+CXCR3+CD7+ and 214 CD8<sup>+</sup>CXCR3<sup>+</sup>CD7<sup>+</sup> subsets, demonstrated substantial capacity for differentiating between R 215 and NR through ROC curve analyses. The AUC values ranged from 0.85 to 1, with p-values 216 from 0.0034 to 0.0415 (Supplementary Figure 9). Notably, CD7 MMI exhibited optimal 217 performance, reaching an AUC of 1 in CD8<sup>+</sup> cells (p = 0.0034). A comparable outcome was 218 obtained using frequencies of marker expression (Supplementary Figure 10). Using the ROC 219 based approach on both MMI (Supplementary Figure 11) and frequencies (Supplementary 220 Figure 12), KM analyses revealed that most markers significantly predicted six-month PFS. 221 We calculated accuracy, negative predictive value (NPV), positive predictive value (PPV), 222 sensitivity, and specificity for these predicted PFS values. The most effective predictors were 223 CD7 MMI in both CD8<sup>+</sup> and CD8<sup>+</sup>CXCR3<sup>+</sup>CD7<sup>+</sup> CAR-T cells. Other markers demonstrated 224 satisfactory accuracy, ranging from 0.77 to 0.92. Notably, several markers exhibited PPV or 225 NPV values of 1, indicating a robust correlation between their expression and six-month PFS. 226

#### 227 Clustering analysis for predicting PFS

228 To further evaluate the predictive potential of specific CAR-T subpopulation frequencies and 229 marker expression levels independently of the known PFS, we assessed whether CXCR3 and CD7 MMI in total CD3<sup>+</sup>CAR<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>CAR<sup>+</sup>, or CD3<sup>+</sup>CD8<sup>+</sup>CAR<sup>+</sup> T cells could 230 231 discriminate between R and NR. One-dimensional k-means clustering was used to categorize 232 MMI expression into two clusters. The predictive accuracy of these clusters for six-month PFS 233 was then evaluated using KM curves. This approach yielded statistically significant results, 234 with p-values ranging from 0.001 to 0.016 for all clusters except CD8<sup>+</sup>CD7<sup>+</sup> MMI (p = 0.1646) 235 (Supplementary Figure 13a-f). These findings indicate that elevated expression levels of 236 CXCR3 and CD7 are associated with enhanced PFS in most T-cell subsets examined. We also 237 applied the same clustering approach to differentiate between R and NR based on the 238 simultaneous expression of multiple markers-CXCR3, CD7, CD71, NKG2D, LAG3, and 239 Ki67 MMI—on the CD3<sup>+</sup>CXCR3<sup>+</sup>CD7<sup>+</sup> population (Supplementary Figure 14a). The 240 silhouette value approach determined an optimal two-cluster solution (Supplementary Figure 241 14b), identifying two distinct clusters: Cluster 1 consisted of four NR, while Cluster 2 included 242 all eight R and one NR. t-SNE visualization showed that the four NR in Cluster 1 clustered closely, whereas the one NR in Cluster 2 was closer to the R (Supplementary Figure 14c). 243 244 This underscores the notable phenotypic distinction of infused CAR-T cells between most NR 245 and R.

246

#### 247 Correlation analysis of marker expression

The clustering analysis demonstrated clear distinctions of CAR T-cell phenotypes independent of infusion product type; NR clustered together regardless of the presence of a CD28 or 4-1BB co-stimulatory domain. This pattern suggests that certain markers are correlated, forming two distinct phenotypes associated with response status. The NR phenotype is characterized by high

expression of LAG3 and CD71 with low levels of CXCR3 and CD7, while the R phenotype exhibits high CXCR3 and CD7 with low LAG3 and CD71.

A correlation matrix of all 39 markers expression across CAR<sup>+</sup>CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> 254 255 compartments revealed intriguing population dynamics. Specifically, positive correlations were 256 observed between CD7 and CXCR3, and between CD71 and LAG3 expressing CAR T-cells. 257 Negative correlations were noted between CXCR3 and LAG3, CD71 and NKG2D, and 258 NKG2D and LAG3 expression (Supplementary Figures 15–17). These negative correlations 259 imply mutual exclusivity among certain markers-for example, high CXCR3 expression 260 coincided with low LAG3 expression. A positive correlation was observed between the 261 frequencies of LAG3 and Ki67-expressing CAR T-cells across all T cell subsets, including total 262 CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> populations. Furthermore, within the CD8<sup>+</sup> CAR T-cell subset, a 263 significant positive correlation was identified between the frequencies of CXCR3 and NKG2D-264 expressing CAR T-cells (Supplementary Figures 18-20).

265

#### 266 Longitudinal analysis of the CXCR3<sup>+</sup>CD7<sup>+</sup> population post-infusion

267 After characterizing the CXCR3<sup>+</sup>CD7<sup>+</sup> population in IPs of both R and NR, and identifying 268 markers linked to long-term remission, we evaluated the population dynamics in circulation up 269 to 30 days post-infusion. Our focus was on the frequency of these cells and alterations in marker 270 expression. At baseline, all patients were lymphopenic. Between Day 3 and 7 post-infusion, 271 CD3<sup>+</sup> cell frequencies increased in both R and NR. However, while there was no difference in 272 the expansion of CAR<sup>-</sup> T-cells, we observed a substantial increase in CAR<sup>+</sup> T-cells only in R 273 (Supplementary Figure 21). Specifically, this expansion was driven by CXCR3<sup>+</sup>CD7<sup>+</sup> CAR<sup>+</sup> T-cells, which reached 12.0% of total CD45<sup>+</sup> cells at Days 7, compared to 2.7% in NR (Figure 274 275 4a). In R, this represented a tenfold increase compared to Day 3, whereas expansion was 276 minimal in NR. In contrast, the frequencies of CXCR3<sup>-</sup>CD7<sup>+</sup>, CXCR3<sup>+</sup>CD7<sup>-</sup>, and double-

277 negative (CXCR3<sup>-</sup>CD7<sup>-</sup>) CAR<sup>+</sup> T-cells remained low and were similar between R and NR 278 (Supplementary Figure 22). Between Days 3 and 10, CXCR3<sup>+</sup>CD7<sup>+</sup> CAR<sup>+</sup> T-cells in R 279 showed significant increases in CXCR3 and Ki67 expression levels, suggesting enhanced 280 proliferation and activation. These increases were not observed in NR (Figure 4b). On Day 7, 281 CXCR3<sup>+</sup>CD7<sup>+</sup> CAR<sup>+</sup> T-cells in R exhibited increased expression of CXCR3 and Ki67 282 compared to NR, while LAG3 levels in NR were non significantly elevated relative to R 283 (Figure 4 c-e). Circulating levels of CXCR3-binding chemokines, CXCL9 and CXCL10, were 284 similarly elevated in both R and NR and did not increase during the expansion phase (Figures 4f-g). These findings indicate that enhanced activation and proliferation of CXCR3<sup>+</sup>CD7<sup>+</sup> 285 286 CAR<sup>+</sup> T-cells are essential for a favorable therapeutic outcome and occur independently of 287 circulating CXCR3-binding chemokine levels.

288 From Day 10 onwards, we observed a significant elevation of perform levels in CXCR3<sup>+</sup>CD7<sup>+</sup> 289 CD3<sup>+</sup> CAR<sup>+</sup> T-cells in R. This increase was not due to changes in CD4<sup>+</sup> or CD8<sup>+</sup> frequencies, 290 as proportions of CD4+CXCR3+CD7+ and CD8+CXCR3+CD7+ cells remained similar between 291 R and NR (Supplementary Figure 23). Apart from perforin, CXCR3, LAG3, and Ki67, no 292 other markers showed a comparable expression pattern over time. These findings suggest that 293 in R, the CXCR3<sup>+</sup>CD7<sup>+</sup> CAR<sup>+</sup> T-cell population not only expands significantly post-infusion, 294 but also shows enhanced proliferative and cytotoxic capabilities. The absence of similar 295 changes in NR underscores the potential role of dynamic shifts in the CXCR3<sup>+</sup>CD7<sup>+</sup> population 296 in mediating effective antitumor responses and achieving long-term remission.

297

#### 298 Discussion

Our study provides novel insights into the phenotypic characteristics of CAR T-cells in standard of care IPs that are associated with long-term remission in patients with R/R DLBCL by identifying specific markers and cell populations that distinguish R from NR. These findings

302 could have substantial implications for predicting treatment outcomes, optimizing CAR-T cell 303 manufacturing processes, and ultimately improving patient outcomes. We observed that the 304 overall CD4/CD8 ratio did not correlate with outcomes, aligning with previous reports 305 suggesting that quantitative global measures of T cell lineage subset content alone may not 306 sufficiently predict clinical responses to CAR T-cell therapy<sup>9</sup>. This prompted a deeper 307 exploration into phenotypic and functional characteristics of CAR T-cell populations. Here, we 308 report differential expression of activation and exhaustion markers between R and NR. NR had 309 higher levels of LAG3, Ki67, and CD71, indicating a state of enhanced activation and potential 310 early exhaustion of CAR-T cells prior to infusion. LAG3 is an inhibitory receptor associated with T cell exhaustion and impaired effector function<sup>10</sup>. It was reported that the disruption of 311 312 LAG3 in CAR T cells enhanced their anti-tumor activity by improving their proliferation and persistence, leading to improved tumor eradication in preclinical models<sup>11,12</sup>, highlighting the 313 314 potential of targeting LAG3 as a tool to improve CAR T-cell efficacy, either by direct 315 modification of CAR-T cells or by combining CAR T-cell therapy with LAG3 inhibitors. 316 Elevated levels of Ki67 and CD71 indicate active proliferation and increased metabolic demand, leading to replicative senescence and reduced persistence after infusion<sup>13</sup>, which may 317 318 contribute to suboptimal clinical outcomes.

319 In contrast, R expressed higher levels of CD3, CD7, CXCR3 and NKG2D. CXCR3 is involved in T-cell trafficking and homing to sites of inflammation and malignancy<sup>14,15</sup>, suggesting 320 321 enhanced migratory capabilities of CAR T cells in R. NKG2D is an activating receptor recognizing stress-induced ligands on tumor cells, contributing to increased cytotoxicity<sup>16,17</sup>. It 322 323 was reported that NKG2D-expressing CAR T-cell therapies, either alone or in combination with 324 other treatments like IL-15 or radiotherapy, may offer an effective approach to enhancing CAR T-cell therapy's efficiency against various cancers<sup>18</sup>. The elevated expression of these receptors 325 326 on CAR T cells suggests that CAR T cells from R are likely endowed with enhanced migratory

13

and effector functions, which facilitates effective tumor localization and eradication. Notably,
the CXCR3<sup>+</sup>CD7<sup>+</sup> double-positive population, enriched in R, was characterized by the strongest
effector potential with detection of high perforin, granzyme B, and NKG2D levels. In contrast,
IPs of NRs contained a higher frequency of CXCR3<sup>+</sup>CD7<sup>+</sup>LAG3<sup>+</sup>CAR<sup>+</sup> T cells, suggesting
CAR-T cell susceptibility to inhibitory signals that might limit efficacy even within potentially
beneficial subsets.

Our results demonstrate that certain markers—such as CD7 MMI in CD8<sup>+</sup> cells—were strongly predictive for six-month progression-free survival. ROC analyses and clustering approaches reinforced the utility of these markers for distinguishing R from NR. R experienced a significant expansion of CXCR3<sup>+</sup>CD7<sup>+</sup>CAR<sup>+</sup> T cells post-infusion, accompanied by increased perforin, Ki67 and CXCR3 expression, indicating enhanced proliferation and activation, necessary prerequisites for achieving sustained remission<sup>19</sup>. The absence of these features in NR, along with upregulated LAG3, may contribute to poorer outcomes.

340 Implementing biomarker assessments, such as incorporating key markers in flow cytometry 341 panels, could improve CAR T-cell product evaluation, inform real-time clinical decisions, and 342 aid in patient stratification. The identified markers could also guide modifications to the CAR 343 T-cell manufacturing process—such as enriching for favorable markers (e.g., 344 CXCR3<sup>+</sup>CD7<sup>+</sup>NKG2D<sup>+</sup>) and depleting those associated with exhaustion (e.g., LAG3<sup>+</sup>). 345 Additional strategies may include engineering CAR T cells to downregulate inhibitory 346 receptors such as LAG3 or overexpress activating receptors like NKG2D, thereby enhancing 347 antitumor activity. The administration of checkpoint inhibitors targeting LAG3 at an early stage 348 may prove beneficial for patients with suboptimal expansion or an elevated level of inhibitory 349 receptors following infusion. These questions require assessment in carefully designed clinical 350 trials.

However, our study's relatively small sample size may limit the generalizability of the findings. Future studies involving larger, multicenter cohorts are needed to validate these biomarkers. Incorporating functional assays alongside phenotypic analysis would also provide a more comprehensive understanding of their roles in mediating therapeutic effects. The immune microenvironment and patient-specific factors may also influence CAR T-cell efficacy, suggesting that a multifaceted approach is needed to fully optimize therapy.

This study underscores the value of phenotypic characterization for predicting clinical outcomes in CAR T-cell therapy. By integrating these biomarkers into clinical protocols, we can enhance patient selection, tailor manufacturing processes, and implement targeted interventions to improve the efficacy of CAR T-cell treatments. Future research should focus on validating and operationalizing these markers to maximize their potential in personalized medicine.

#### 363 Figures legend

#### 364 Figure 1: Marker expression in CD3<sup>+</sup> CAR<sup>+</sup> T-cells

Expression of CD3, CD7, CD71, CXCR3, CXCR5, Ki67, LAG3 and NKG2D in CD3<sup>+</sup>CAR<sup>+</sup> T-cells, expressed both as MMI (a) and as frequency (b) of the parent population. Marker expression was measured in the total CD3<sup>+</sup> population (a-b), in the cytotoxic (c-d) (CD3<sup>+</sup>CD8<sup>+</sup>) and in the helper (e-f) (CD3<sup>+</sup>CD4<sup>+</sup>) compartment. Responders=blue, n=8. Non-responders=red, n=5. Statistical significance was determined using the Mann-Whitney U-Test, with significance levels indicated as \*p<0.05 and \*\*p<0.01.

Figure 2: Frequencies of double and triple positive CAR T-cells. (a) Frequencies of doublepositive CXCR3<sup>+</sup>CD7<sup>+</sup> cells as a percentage of CAR<sup>+</sup>CD3<sup>+</sup>, CAR<sup>+</sup>CD3<sup>+</sup>CD4<sup>+</sup>, and
CAR<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup> cells in responders (blue, n=8) vs. non-responders (red, n=5), (b-d)
Frequencies of triple-positive CXCR3<sup>+</sup>CD7<sup>+</sup> (LAG3<sup>+</sup>NKG2D<sup>+</sup>CD71<sup>+</sup>) cells as a percentage of

375	CAR+CD3+, CAR+CD3+CD4+, and CAR+CD3+CD8+ cells in responders (blue, n=8) vs. non-
376	responders (red, n=5). Memory T-cell frequencies from healthy controls (yellow, n=10) are
377	provided as a baseline reference. Statistical significance determined via Mann-Whitney U-Test
378	with *p<0.05 and **p<0.01.

379

#### 380 Figure 3: Marker ratios as predictive tools for six-month PFS

381 (a) Ratios of positive/negative populations for CD71, LAG3, and NKG2D in 382 CAR+CXCR3+CD7+CD3+ (a), CD3+CD4+ (b), and CD3+CD8+ (c) cells in responders (blue, 383 n=8) vs. non-responders (red, n=5). NKG2D in CD4<sup>+</sup> is excluded due to lack of expression. 384 Statistical significance determined by Mann-Whitney U-Test (\*p<0.05, \*\*p<0.01), (d) 385 Summary table of predictive power using marker ratios calculated with optimal cutoff values 386 determined via the Youden index. New predicted PFS accuracies, positive predictive value 387 (PPV), negative predictive value (NPV), sensitivities, and specificities are reported. (e-f) ROC 388 and AUC for the ratio of LAG3 in CD4+ and NKG2D in CD8+ and (g-h) association of the 389 respective ratio cutoff to progression free survival.

390

# Figure 4: Longitudinal analysis of CXCR3<sup>+</sup>CD7<sup>+</sup> CD3<sup>+</sup>CAR<sup>+</sup> T-cell frequency and marker expression

(a) Frequency of CAR<sup>+</sup>CD3<sup>+</sup>CXCR3<sup>+</sup>CD7<sup>+</sup> cells in patient circulation (% of total CD45<sup>+</sup>
events) from Day 3 to Day 30 post-infusion (responders in blue, non-responders in red), (b)
Fold change in frequency of CXCR3<sup>+</sup>CD7<sup>+</sup> (CAR<sup>+</sup>CD3<sup>+</sup>, % of total CD45<sup>+</sup> events) from Day 3
to Day 10, comparing responders (n=8, blue) to non-responders (n=5, red) (c-d) Paired analysis
of CXCR3 (as MMI), Ki67 and LAG3 expression fluctuations (as frequency) in the
CXCR3<sup>+</sup>CD7<sup>+</sup> population in responders (blue) and non-responders (red) between Days 3 and
10. (e) Associated graphs showing fold change in CXCR3, Ki67 and LAG3 MMI between Days

400 3 and 7. (f-g) Levels of CXCR3-binding chemokines CXCL9 and CXCL10 in circulation of 401 responders (blue) and non-responders (red) at Day 0 (infusion), Day 4, and Day 10 post-402 infusion, with associated graphs showing fold changes in cytokine levels from Day 4 to Day 403 10. Statistical significance was assessed using the Mann-Whitney U-Test, with significance 404 levels indicated as \*p<0.05 and \*\*p<0.01. The line shown within each box plot represents the 405 median.

406

#### 407 Acknowledgements

This work was supported by the strategic plan of the CHUV. We would like to express ourgratitude to all the patients who generously contributed their time and samples for this project.

410

#### 411 Author contributions

412 MO designed the study and supervised the analysis. MO, RB and DD drafted the manuscript. 413 MO, RB and DD had full access to all data in the study and take responsibility for its integrity 414 and accuracy. MO, DD, RB, LT and CA collected the data. AN, CF, MP, GP and MO developed 415 the CAR T-cell panel. RB, DD, VJ, CA, BG, LT and MO analyzed, interpreted and discussed 416 the data. LT, RS and CA recruited patients and supervised the clinical treatments. MO 417 participated in the clinical treatments. RB, DD, VJ and MO prepared the figures. GC and GP 418 participated in the scientific discussion. The manuscript was reviewed and approved by all 419 authors before submission.

420

#### 421 **Conflict of interest**

MO received honoraria and speaker fees from Moderna, Roche and BMS. C.A. holds patents
and provisional patent applications in the field of engineered T cell therapies. C.A. receives
licensing fees and royalties from Immatics (through previous institution Baylor College of

425 Medicine), participated in advisory boards for Kite/ Gilead, Janssen and Celgene/ BMS, 426 received sponsored travel from Gilead (through current institution Lausanne University 427 Hospital (CHUV). G.C. has received honoraria from Bristol-Myers Squibb. CHUV has 428 received honoraria for advisory services provided by G.C. to Iovance and EVIR. G.C. has 429 received royalties from the University of Pennsylvania for CAR T cell therapy licensed to 430 Novartis and Tmunity Therapeutics. G.C. has received royalties from the Ludwig Institute for 431 Cancer Research, UNIL and CHUV for NeoTIL intellectual property previously licensed to 432 Tigen Pharma. G.C. is inventor in technologies related to T cell expansion and engineering for 433 T cell therapy. RS participated in advisory boards for Janssen, Celgene/ BMS, AbbVie, Takeda 434 and Incyte.

435

#### 436 Data sharing statements

437 The datasets supporting the results of this study are not publicly available. Requests for access

438 to the dataset will be granted upon reasonable request to the principal investigator. Study data

439 will be managed, stored, shared, and archived according to CHUV standard operating

440 procedures to ensure the continued quality, integrity, and utility of the data.

441

#### 442 References

4431.Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse444Large B-Cell Lymphoma. N Engl J Med 2019;380(1):45-56. DOI: 10.1056/NEJMoa1804980.

- Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells
  derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.
  Leukemia 2016;30(2):492-500. DOI: 10.1038/leu.2015.247.
- 4483.Deng Q, Han G, Puebla-Osorio N, et al. Characteristics of anti-CD19 CAR T cell infusion products449associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med4502020;26(12):1878-1887. DOI: 10.1038/s41591-020-1061-7.

451 4. Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1
452 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 2016;126(8):3130-44. DOI:
453 10.1172/JCI83092.

- 4545.Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor455(CAR)-modified T cells: refueling the CAR. Blood 2017;129(8):1039-1041. DOI: 10.1182/blood-4562016-09-738245.
- 4576.Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19458chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med4592018;24(5):563-571. DOI: 10.1038/s41591-018-0010-1.
- 4607.Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know461so far. Nat Rev Clin Oncol 2023;20(6):359-371. DOI: 10.1038/s41571-023-00754-1.
- 462 8. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release
  463 Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow
  464 Transplant 2019;25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758.
- 4659.Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19466chimeric antigen receptors. Nat Rev Clin Oncol 2013;10(5):267-76. DOI:46710.1038/nrclinonc.2013.46.
- 46810.Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and469CTLA-4: breakthroughs or backups. Nat Immunol 2019;20(11):1425-1434. DOI:47010.1038/s41590-019-0512-0.
- 471
   11.
   Zhang Y, Zhang X, Cheng C, et al. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Front

   472
   Med 2017;11(4):554-562. DOI: 10.1007/s11684-017-0543-6.
- 47312.Zou F, Lu L, Liu J, et al. Engineered triple inhibitory receptor resistance improves anti-tumor474CAR-T cell performance via CD56. Nat Commun 2019;10(1):4109. DOI: 10.1038/s41467-019-47511893-4.
- 47613.Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol4772015;15(8):486-99. DOI: 10.1038/nri3862.
- 47814.Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha479(SIRPalpha) and CD47: structure, function, and therapeutic target. Annu Rev Immunol4802014;32:25-50. DOI: 10.1146/annurev-immunol-032713-120142.
- 481
   15.
   Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res 2011;317(5):620-31. DOI:

   482
   10.1016/j.yexcr.2010.12.017.
- 48316.Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, Mirzaei HR, Hadjati J. Prolonged Persistence of<br/>Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and<br/>Ways Forward. Front Immunol 2020;11:702. DOI: 10.3389/fimmu.2020.00702.
- 486
   17.
   Lanier LL. NKG2D Receptor and Its Ligands in Host Defense. Cancer Immunol Res 2015;3(6):575 

   487
   82. DOI: 10.1158/2326-6066.CIR-15-0098.
- 48818.Mai Q, He B, Deng S, et al. Efficacy of NKG2D CAR-T cells with IL-15/IL-15Ralpha signaling for<br/>treating Epstein-Barr virus-associated lymphoproliferative disorder. Exp Hematol Oncol<br/>2024;13(1):85. DOI: 10.1186/s40164-024-00553-z.
- 49119.Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in492Refractory Large B-Cell Lymphoma. N Engl J Med 2017;377(26):2531-2544. DOI:49310.1056/NEJMoa1707447.

494

### **Graphical Abstract**

#### Identification of phenotypic markers within CAR+ T-cell products that predict long-term remission in <u>DLBCL patients</u>



## <u>Table 1</u>

	N=13	% within cohort
Age		
 Median	61	
≥ 65 years	6	46%
Gender		
Female	3	23%
Male	10	77%
Tumor Type		
DLBCL	13	100%
Initial Stage		
I-II	6	46%
	7	54%
CAR T-cell type		
Axicabtagene ciloleucel	11	85%
Tisagenlecleucel	2	15%
Cytokines release Syndrome (CRS)		
Grading		
No CRS	2	15%
G1-G2	10	77%
G3-G4	1	15%
G5	0	0%
Immune Effector Cell-Associated Neurotoxicity Sy	ndrome (ICANS)	
Grading		
No ICANS	6	46%
G1-G2	3	23%
G3-G4	4	31%
G5	0	0%
Immune Effector Cell-Associated Hematological Te	oxicity (ICAHT)	
<u>Late (&gt;30 days)</u>		
Pancytopenia	2	15%
Anemia	2	15%
Thrombocytopenia	5	38%
Neutropenia	4	31%
Immunosuppressive treatment		
Corticosteroids (CS)	5	38%
Tocilizumab (TCZ)	11	85%
Canakinumab (CAN)	1	8%







		Cuto	ff to be R							
Population of CarT+	Marker	Sign	Cutoff	ROC AUC	P AUC	Accuracy	PPV	NPV	Sensitivity	Specificity
	CD71	<	4.74	0.9	0.0192	0.85	0.88	0.80	0.88	0.80
	LAG3	<	0.83	0.95	0.0084	0.92	0.89	1.00	1.00	0.80
CD/+	NKG2D	>	1.034	0.775	0.1073	0.69	1.00	0.56	0.50	1.00
CD4+ CXCR3+	CD71	<	5.14	0.9	0.0192	0.85	0.88	0.80	0.88	0.80
CD7+	LAG3	<	0.5601	0.9	0.0192	0.92	0.89	1.00	1.00	0.80
	CD71	<	4.058	0.825	0.057	0.77	1.00	0.63	0.63	1.00
	LAG3	<	0.7132	0.925	0.0128	0.85	1.00	0.71	0.75	1.00
CD/+	NKG2D	>	3.188	0.975	0.0054	0.92	1.00	0.83	0.88	1.00





